Binx Health secured $65M in series F financing led by Hildred Capital and EQT Life Sciences Partner to fuel its growth
Binx Health secured $65M in series F financing led by Hildred Capital and EQT Life Sciences Partner to fuel its growth
04/04/24, 2:50 PM
Location
Money raised
$65 million
Industry
medical
biotechnology
health care
Round Type
series f
Investors
Eqt Life Sciences Partner, Hildred Capital
Binx Health has raised $65 million in series F financing to support commercial sales and high-volume manufacturing of its point-of-care molecular platform for diagnosing chlamydia and gonorrhea. The funding includes equity, debt, and expanded lease facility financing.
Company Info
Location
245 first st, riverview ii, 18th floor
cambridge, massachusetts, united states
Additional Info
Binx Health is a health technology company aiming to speed up the time between diagnosis and treatment of sexually transmitted infections with a point-of-care diagnostic solution. The company developed the Binx io point-of-care molecular platform, an FDA-cleared, CLIA-waived system, that can be used in doctors' offices, urgent care clinics and hospital emergency rooms to quickly diagnose chlamydia and gonorrhea for both men and women. Binx's point-of-care platform makes STI testing more convenient, accessible and discreet for patients.